Product Description
autologous adipose tissue derived mesenchymal stem cells (AdMSC) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02674399)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: R-Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BSR-CTph3-JS1_FU | P3 |
Active, not recruiting |
Osteoarthritis, Knee |
2026-12-23 |
15% |
| JS-OAP3-US01 | P3 |
Recruiting |
Osteoarthritis, Knee |
2024-06-30 |
15% |